Arrowhead制药公司宣布在国际肝脏大会（TM）

StephenW

Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress(TM)


    PASADENA, Calif.--(BUSINESS WIRE)--      Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it      will present clinical data on ARC-520, ARC-521, and ARC-AAT, the      company's prior generation investigational medicines that were being      studied for the treatment of chronic hepatitis B infection and liver      disease associated with alpha-1 antitrypsin deficiency, at The      International Liver Congress™ 2017 (ILC), the annual meeting of the      European Association for the Study of the Liver (EASL) being held in      Amsterdam, the Netherlands from April 19-23, 2017.   
          Oral Presentations:   
          Prolonged RNA interference therapy with ARC-520 Injection in      treatment naïve, HBeAg positive and negative patients with chronic HBV      results in significant reductions of HBs antigen   
   

•         Presentation Reference: PS-045
•         Session: Parallel session: Hepatitis B and D: Emerging treatment        options
•         Date and Time: April 20, 2017 at 5:30 PM CET
•         Authors: Man-Fung Yuen, et al.
  

          Hepatic targeted RNA interference provides deep and prolonged      knockdown of alpha-1 antitrypsin levels in ZZ patients   
   

•         Presentation Reference: LBO-06
•         Session: Late Breaker session
•         Date and Time: April 22, 2017 at 5:15 PM CET
•         Authors: Alice Turner, et al.
  

          Poster Presentation:   
          A phase 1 study to evaluate safety and tolerability of escalating      single doses of the HBV RNA interference drug ARC-521 in a healthy      volunteer population   
   

•         Presentation Reference: THU-176
•         Session: Viral hepatitis: Hepatitis B and D - Clinical (therapy, new        compounds, resistance)
•         Session Date and Time: April 20, 2017 from 8:00 AM to 6:00 PM CET
•         Authors: Edward Gane, et al.
  

          Additional details including presentation abstracts can be found on the      ILC website at https://ilc-congress.eu/.      A copy of presentation materials can be accessed by visiting the Events      section of the Arrowhead website after the presentations conclude.   
          Arrowhead announced on November 29, 2016 that it had discontinued      development of ARC-520, ARC-521, and ARC-AAT. The company continues to      develop ARO-HBV and ARO-AAT, which are follow on investigational RNAi      therapeutics against chronic hepatitis B infection and alpha-1 liver      disease that utilize the company's new proprietary subcutaneous delivery      system.   
          The International Liver Congress is a trademark of the European      Association for the Study of the Liver.   

StephenW

Arrowhead制药公司宣布在国际肝脏大会（TM）


（纳斯达克股票代码：ARWR）今天宣布，ARC-520，ARC-521和ARC-AAT将临床临床应用，该公司以前的代理研究þ在研究治疗慢性乙型肝炎感染和与α- 1抗胰蛋白酶缺乏症，国际肝脏大会™2017（ILC），欧洲肝脏研究协会（EASL）年会将于2017年4月19日至23日在荷兰阿姆斯特丹举行

口头报导：

长时间的RNA干扰治疗与ARC-520注射治疗初治HBeAg阳性和阴性慢性HBV患者HBs抗原显着降低

介绍参考：PS-045
会议：平行会议：乙型和丙型：新出现的治疗方案
日期和时间：2017年4月20日下午5:30
作者：Man-Fung Yuen，et al。

肝脏靶向RNA干扰ZZ患者的α-1抗胰蛋白酶水平的深度和延长的敲低

演示文稿参考：LBO-06
会话：断层会话
日期和时间：2017年4月22日下午5:15 CET
作者：Alice Turner，et al。

海报演示：

评估阳性志愿人群中单次剂量HBV RNA干扰药物ARC-521的安全性和耐受性的第1期研究

演示文稿参考：THU-176
会议：病毒性肝炎：乙型和丙型肝炎临床（治疗，新化合物，抗药性）
会议日期和时间：2017年4月20日上午8:00至下午6:00
作者：Edward Gane，et al。

有关演示摘要的其他详细信息，请访问ILC网站https://ilc-congress.eu/。在演示结束后，可以访问“箭头”网站的“活动”部分，访问演示材料的副本。

Arrowhead于2016年11月29日发布，已经停止了ARC-520，ARC-521和ARC-AAT的开发。该公司继续开发ARO-HBV和ARO-AAT，这些研究是针对慢性乙型肝炎感染和α-1肝病的研究性RNAi治疗剂，其占据了该公司新的专有皮下递送系统。

国际肝脏大会是欧洲肝脏研究协会的商标。

齐欢畅2

Arrowhead Pharmaceuticals Announces Presentations at The International Liver
Congress™
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will
present clinical data on ARC-520, ARC-521, and ARC-AAT, the company's prior generation investigational medicines that
were being studied for the treatment of chronic hepatitis B infection and liver disease associated with alpha-1 antitrypsin
deficiency, at The International Liver Congress™ 2017 (ILC), the annual meeting of the European Association for the Study
of the Liver (EASL) being held in Amsterdam, the Netherlands from April 19-23, 2017.
Oral Presentations:
Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative
patients with chronic HBV results in significant reductions of HBs antigen
Š Presentation Reference: PS-045
Š Session: Parallel session: Hepatitis B and D: Emerging treatment options
Š Date and Time: April 20, 2017 at 5:30 PM CET
Š Authors: Man-Fung Yuen, et al.
Hepatic targeted RNA interference provides deep and prolonged knockdown of alpha-1 antitrypsin levels in ZZ
patients
Š Presentation Reference: LBO-06
Š Session: Late Breaker session
Š Date and Time: April 22, 2017 at 5:15 PM CET
Š Authors: Alice Turner, et al.
Poster Presentation:
A phase 1 study to evaluate safety and tolerability of escalating single doses of the HBV RNA interference drug
ARC-521 in a healthy volunteer population
Š Presentation Reference: THU-176
Š Session: Viral hepatitis: Hepatitis B and D - Clinical (therapy, new compounds, resistance)
Š Session Date and Time: April 20, 2017 from 8:00 AM to 6:00 PM CET
Š Authors: Edward Gane, et al.
Additional details including presentation abstracts can be found on the ILC website at https://ilc-congress.eu/. A copy of
presentation materials can be accessed by visiting the Events section of the Arrowhead website after the presentations
conclude.
Arrowhead announced on November 29, 2016 that it had discontinued development of ARC-520, ARC-521, and ARC-AAT.
The company continues to develop ARO-HBV and ARO-AAT, which are follow on investigational RNAi therapeutics against
chronic hepatitis B infection and alpha-1 liver disease that utilize the company's new proprietary subcutaneous delivery
system.
The International Liver Congress is a trademark of the European Association for the Study of the Liver.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA
interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a
specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to
the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of
the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking
statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the
duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of
our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials,
rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual
Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may
affect our business, results of operations and financial condition. We assume no obligation to update or revise forwardlooking
statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170405005323/en/

齐欢畅2

ARO-HBV

ARO-HBV is being developed to be a potentially curative therapy for patients with chronic hepatitis B infection. ARO-HBV silences all HBV gene products and intervenes upstream of the reverse transcription process where current standard-of-care nucleotide and nucleoside analogues act. The company believes this will allow the body’s natural immune defenses to clear the virus and lead to a functional cure.

Disease

Chronic hepatitis B infection is the most common serious liver infection. Current drugs suppress viral replication but rarely lead to a cure and therefore must be taken indefinitely. Developing curative therapy is a priority.

There are 16 million people with chronic hepatitis B in the U.S. and Western Europe and 400 million people worldwide. In the immune tolerant phase of chronic infection, which can last for many years, the infected person typically produces very high levels of viral DNA and viral antigens. However, the infection is not cytotoxic and the carrier may have no symptoms of illness. Over time, the ongoing production of viral antigens causes inflammation and necrosis, leading to cirrhosis and liver cancer (HCC). Hepatitis B is responsible for 80% of primary liver cancers.

The current standard of care for treatment of chronic HBV infection is a daily oral dose of nucleotide/nucleoside analogs (NUCs) or a regimen of interferon injections for approximately one year. NUCs are generally well tolerated, but patients may need lifetime treatment because viral replication often rebounds upon cessation of treatment. Interferon therapeutics can result in a functional cure in around 10% of some patient types, but treatment is often associated with significant side effects, including severe flu-like symptoms, bone marrow suppression, and autoimmune disorders.

Close

齐欢畅2

newchinabok

不太懂，太不懂

kite2002005

感觉他是阵亡了

gyh888559

起死回生了吗。好事多磨阿

hao2014

啥意思？？能不能说说？？